Pharma & Bio
Business·Industry
'Cumulative Technology Transfer Value Reaches 3 Trillion Won': Aimed Bio Sees a Series of ADC Technology Transfers
#AimedBio is drawing attention for achieving a cumulative total of 3 trillion won in technology transfer deals while still in the unlisted and preclinical stages. AimedBio was listed on the KOSDAQ mar…
Technology
'Insurance for Baldness?' Policy Hopes Drive 30% Surge in JW Pharma [K-bio Pulse]
The government’s plan to review health insurance coverage for hair-loss treatments triggered sharp price movements in Korea’s pharmaceutical and biotech sectors on June 15. Hair-loss drug manufacturer…
Technology
“Hair Loss Stock Day”… JW New Drug, Hyundai Pharmaceutical, and Samik Pharmaceutical Rise on Policy Momentum [Bio Spotlight]
On the 15th, the domestic pharmaceutical and biotech sector was in turmoil following news that the government is considering covering hair loss treatments under the national health insurance system. W…
Technology
"Hiring 'Robot Researchers Who Work Nonstop'... JW Pharmaceutical Sets a New Standard for Clinical Trials"
Autonomous laboratories utilizing artificial intelligence (AI) and robots are revolutionizing new drug development. We have entered an era where automation extends beyond simple, repetitive tasks to i…
Business·Industry
HLB, 'Ahead of Approval for New Liver Cancer Drug,' May Substitute Written Submission for CMC Inspection… Industry Skepticism
With the decision on whether #HLB’s new liver cancer drug, Riboceranib, will receive U.S. approval just over a month away, the possibility of a Regulatory Review Information (RLI) report has been rais…
Lifestyle
'Structural Reform Success' Y2Solution Forecasts Doubling of This Year's Earnings
#Y2Solution is continuing its rapid growth toward doubling its performance this year, having successfully shed the constraints of traditional manufacturing and transformed itself into a high-tech comp…
Technology
Y-Bio Bets on Its Own Pipeline… Aims for Early Technology Transfer with Triple-Antibody
#Y-Biologics is aiming for early-stage technology transfer in the preclinical phase, leveraging its proprietary trivalent antibody.Y-Biologics is shifting its focus from an antibody platform company t…
Manufacturing
‘From Low-Molecular-Weight Compounds to Antibody Platform’: Abion Advances Its Business... Also Pursuing Additional Technology Transfers
#Abion is seeking to transform itself from a new drug development company into an antibody platform company. While Abion has previously focused on developing new small-molecule drugs, it is now upgrad…
Lifestyle
Semiconductor Rally Dominates...But Profit-Driven JLK and DT&CRO Surge on Solid Earnings [K-Bio Pulse]
As capital continued to flow into the semiconductor sector in the domestic stock market, the biotech and medical technology sectors also saw steady valuation gains, particularly among companies backed…
Lifestyle
Amid a Strong Semiconductor Market, JLK and DT&CR Rise on Strong Earnings [Bio Spotlight]
Amid the ongoing concentration of investment in the semiconductor sector in the domestic stock market, the biotech sector has also shown a steady upward trend in value, led by companies with solid ear…